Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference

Decibel Therapeutics, a development-stage biotechnology company creating novel therapeutics for hearing loss and balance disorders, will present new findings from several of their drug discovery and development programs at the 43rd annual meeting of the Association for Research in Otolaryngology, which is being held from January 25-29 in San Jose, CA.

Data to be presented at the conference showcase how Decibel's drug discovery and translational platform is enabling the development of an array of therapeutic programs, including DB-020 to treat cisplatin-induced ototoxicity and a gene therapy to treat congenital deafness caused by a deficiency in the otoferlin gene. In an invited symposium, Jonathon Whitton, Au.D., Ph.D., director of clinical development, will highlight how Decibel has leveraged its industry-leading, single-cell genomics and bioinformatics capabilities as part of a broader gene therapy platform to optimize therapeutic solutions for hearing loss and balance disorders.

"Over the past year, we have made significant advances in a number of our programs. These developments demonstrate the strength of our unique approach and will continue to enable our efforts in restoration and regenerative medicine approaches to the inner ear," said John Lee, executive vice president, pharmaceutical development.

The Decibel team will have a total of eight posters and presentations during this year's meeting.

Podium Presentations

SYMP 12 | Moving Gene Therapies for Hearing Loss into the Clinic
Date & Time: Saturday, January 25, 3:15 p.m. PT

PD 35 | Dissecting the Differentiation Fates of Hair Cells in the Vestibular Sensory Epithelia during Mouse Inner Ear Development using Single Cell Transcriptomics
Date & Time: Sunday, January 26, 11:00 a.m. PT

Poster Presentations

PS 60 | Development of Middle-Ear-Muscle Reflex (MEMR) Biomarker in Mouse

PS 143 | Multivariate Polygenic Risk Scores Identify Individuals At-Risk for and Protected from Hearing Loss

PS 184 | Natural History and Disease Progression in Two Rodent Models of Monogenic Hearing Loss

PS 463 | DB-020 Protects Cells from Cisplatin Cytotoxicity in vitro and Hair Cells in a Guinea Pig Model of Cisplatin Induced Ototoxicity

PS 692 | Tailored AAV-based Transgene Expression in the Inner Ear with Cell Type-Specific Promoters

PS 714 | Characterization of an Acute and Cyclic Cisplatin-Induced Hearing Loss in Male Fischer-344 Rats

About Decibel Therapeutics, Inc.
Decibel Therapeutics, a development-stage biotechnology company, has established the world's first comprehensive drug discovery, development and translational research platform for hearing and balance disorders. Decibel is advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all. Decibel's lead therapeutic candidate, DB-020, is being investigated for the prevention of ototoxicity associated with cisplatin chemotherapy. For more information about Decibel Therapeutics, please visit decibeltx.com or follow @DecibelTx.

These press releases may also interest you

at 14:45
Bluebird Network ? Midwest communications infrastructure provider and data center owner ? continues its mission of supporting the communities it serves by partnering with Impact 4 Good and River City Habitat for Humanity to provide supplies for...

at 14:44
Steampunk is proud to announce the completion of their first Design Intelligencetm Studio, a creative human-centered design workspace, which is co-located with their corporate headquarters in McLean, Virginia....

at 14:39
Cision, an industry-leading earned media communications management and media advisory platform, today published the latest data from its 2020 State of the Election blog series, a weekly nonpartisan media analysis of the U.S. presidential election....

at 14:39
CEIA USA, a premier provider of high-performance Security Metal Detectors, today announced the availability of a new anti-COVID security solution, the CEIA TDU (Thermal Detection Unit) upgrade sensing kit. This system provides the ability to include...

at 14:39
SANS Institute, the global leader in cyber security training and certifications, today announced that the call for nominations for the SANS 2020 Difference Makers Awards is now open. SANS is accepting nominations for individuals, teams, and groups...

at 14:30
Phase Genomics, Inc., the biotech leader providing proximity-ligation solutions for the genomics community, announced today the receipt of two NIH grants totaling $3.9M. The funds will be utilized to develop new, highly-scalable methods for detecting...

News published on 24 january 2020 at 08:35 and distributed by: